
Lars-Olof Hattenbach

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4921582/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Intravitreous injection of tissue plasminogen activator and gas in the treatment of submacular hemorrhage under various conditions. Ophthalmology, 2001, 108, 1485-1492.	2.5	150
2	Intravenous Thrombolysis With Low-dose Recombinant Tissue Plasminogen Activator in Central Retinal Artery Occlusion. American Journal of Ophthalmology, 2008, 146, 700-706.e1.	1.7	110
3	Risk Factors for Complications After Congenital Cataract Surgery without Intraocular Lens Implantation in the First 18 Months of Life. American Journal of Ophthalmology, 2008, 146, 1-7.e1.	1.7	97
4	Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study. American Journal of Ophthalmology, 2016, 169, 258-267.	1.7	66
5	Factor XII deficiency: A thrombophilic risk factor for retinal vein occlusion. American Journal of Ophthalmology, 2004, 137, 459-464.	1.7	65
6	Incidence of posterior vitreous detachment after cataract surgery. Journal of Cataract and Refractive Surgery, 2009, 35, 987-991.	0.7	62
7	Course of Intraocular Pressure after Intravitreal Injection of 0.05 mL Ranibizumab (Lucentis [®]). European Journal of Ophthalmology, 2010, 20, 174-179.	0.7	58
8	Coagulation disorders and the risk of retinal vein occlusion. Thrombosis and Haemostasis, 2010, 103, 299-305.	1.8	56
9	Subretinal Hemorrhages Associated with Age-Related Macular Degeneration in Patients Receiving Anticoagulation or Antiplatelet Therapy. American Journal of Ophthalmology, 2010, 149, 316-321.e1.	1.7	53
10	High prevalence of resistance to APC in young patients with retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology, 2002, 240, 163-168.	1.0	49
11	Headâ€ŧoâ€head comparison of ranibizumab PRN versus singleâ€dose dexamethasone for branch retinal vein occlusion (COMRADEâ€B). Acta Ophthalmologica, 2018, 96, e10-e18.	0.6	48
12	Reactivation of Toxoplasma Retinochoroiditis Under Atovaquone Therapy in an Immunocompetent Patient. Ocular Immunology and Inflammation, 2006, 14, 185-187.	1.0	47
13	Fibrinolytic Therapy with Low-Dose Recombinant Tissue Plasminogen Activator in Retinal Vein Occlusion. Ophthalmologica, 1998, 212, 394-398.	1.0	45
14	Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (<scp>RABAMES</scp>): sixã€month results of a prospective randomized clinical trial. Acta Ophthalmologica, 2015, 93, e29-37.	0.6	45
15	Pigment-Epithelium-Derived Factor Is Upregulated in Photocoagulated Human Retinal Pigment Epithelial Cells. Ophthalmic Research, 2005, 37, 341-346.	1.0	42
16	Visual Outcome after Treatment with Low-Dose Recombinant Tissue Plasminogen Activator or Hemodilution in Ischemic Central Retinal Vein Occlusion. Ophthalmologica, 1999, 213, 360-366.	1.0	41
17	Central Retinal Vein Occlusion and Nonarteritic Ischemic Optic Neuropathy in 2 Patients with Mild Iron Deficiency Anemia. Ophthalmologica, 2001, 215, 128-131.	1.0	41
18	RETINAL VEIN OCCLUSION AND LOW-DOSE FIBRINOLYTIC THERAPY (R.O.L.F.). Retina, 2009, 29, 932-940.	1.0	35

LARS-OLOF HATTENBACH

#	Article	IF	CITATIONS
19	Ophthalmic manifestation of congenital protein C deficiency. Journal of AAPOS, 1999, 3, 188-190.	0.2	33
20	Detection of Inducible Nitric Oxide Synthase and Vascular Endothelial Growth Factor in Choroidal Neovascular Membranes. Ophthalmologica, 2002, 216, 209-214.	1.0	33
21	VITREOUS CONCENTRATIONS OF TPA AND PLASMINOGEN ACTIVATOR INHIBITOR ARE ASSOCIATED WITH VEGF IN PROLIFERATIVE DIABETIC VITREORETINOPATHY. Retina, 1999, 19, 383.	1.0	33
22	Intraocular recombinant tissue-plasminogen activator fibrinolysis of fibrin formation after cataract surgery in children. Journal of Cataract and Refractive Surgery, 1999, 25, 357-362.	0.7	32
23	Intravitreal Sustained-Release Steroid Implants for the Treatment of Macular Edema following Surgical Removal of Epiretinal Membranes. Ophthalmologica, 2017, 237, 232-237.	1.0	28
24	Experimental Percutaneous Cannulation of the Supraorbital Arteries: Implication for Future Therapy. , 2005, 46, 1557.		27
25	Factors predicting normal visual acuity following anatomically successful macular hole surgery. Acta Ophthalmologica, 2021, 99, e324-e329.	0.6	24
26	Recurrent retinal vein occlusion in a patient with increased plasma levels of histidine-rich glycoprotein. American Journal of Ophthalmology, 2003, 135, 232-234.	1.7	23
27	Comparison of ranibizumab versus dexamethasone for macular oedema following retinal vein occlusion: 1â€year results of the <scp>COMRADE</scp> extension study. Acta Ophthalmologica, 2018, 96, e933-e941.	0.6	22
28	Optical Coherence Tomography for Diagnosis of Posterior Vitreous Detachment at the Macular Region. European Journal of Ophthalmology, 2009, 19, 442-447.	0.7	21
29	Selective thrombophilia screening of patients with nonarteritic anterior ischemic optic neuropathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2009, 247, 485-490.	1.0	21
30	Identification of Beta-Defensins in Human Conjunctiva. Antimicrobial Agents and Chemotherapy, 1998, 42, 3332-3332.	1.4	20
31	Retinal Vascular Occlusions. Deutsches Ärzteblatt International, 2008, 105, 474-9.	0.6	20
32	Impact of the SARS-CoV-2 pandemic on ophthalmic care in Germany. Ophthalmologe, 2021, 118, 166-175.	0.4	16
33	Massive subhyaloidal hemorrhage associated with severe PAI-1 deficiency. Graefe's Archive for Clinical and Experimental Ophthalmology, 2005, 243, 963-966.	1.0	15
34	Pneumatic retinopexy: A critical reappraisal. Survey of Ophthalmology, 2021, 66, 585-593.	1.7	15
35	Sphingosine Kinase 2 Modulates Retinal Neovascularization in the Mouse Model of Oxygen-Induced Retinopathy. , 2018, 59, 653.		14
36	Modulation of tissue plasminogen activator and plasminogen activator inhibitor-1 by transforming growth factor-beta in human retinal glial cells. Investigative Ophthalmology and Visual Science, 2002, 43, 2799-805.	3.3	14

#	Article	IF	CITATIONS
37	Retrospective, Observational Study in Patients Receiving a Dexamethasone Intravitreal Implant 0.7 mg for Macular Oedema Secondary to Retinal Vein Occlusion. Ophthalmologica, 2015, 233, 18-26.	1.0	13
38	Elevated lipoprotein (a) levels are an independent risk factor for retinal vein occlusion. Acta Ophthalmologica, 2017, 95, 140-145.	0.6	12
39	Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular AMD. Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260, 1843-1856.	1.0	12
40	VITREOUS CONCENTRATIONS OF TPA AND PLASMINOGEN ACTIVATOR INHIBITOR ARE ASSOCIATED WITH VEGF IN PROLIFERATIVE DIABETIC VITREORETINOPATHY. Retina, 1999, 19, 383-389.	1.0	11
41	Platelet activation by ADP is increased in selected patients with anterior ischemic optic neuropathy or retinal vein occlusion. Platelets, 2017, 28, 720-723.	1.1	11
42	Pigment Epithelium Endoscopic Laser Surgery for Treatment of Choroidal Neovascularization. Ophthalmologica, 2004, 218, 162-175.	1.0	10
43	Intraocular Levels of Methotrexate after Oral Low-Dose Treatment in Chronic Uveitis. Ophthalmologica, 2005, 219, 54-55.	1.0	10
44	Prothrombin polymorphism A19911G, factor V HR2 haplotype A4070G, and plasminogen activator-inhibitor-1 polymorphism 4G/5G and the risk of retinal vein occlusion. Ophthalmic Genetics, 2017, 38, 413-417.	0.5	10
45	Electrophysiological Retinal Pigment Epithelium Changes Observed with Indocyanine Green, Trypan Blue and Triamcinolone. Ophthalmic Research, 2010, 44, 17-23.	1.0	9
46	Selective Thrombophilia Screening in Young Patients with Retinal Artery Occlusion. Ophthalmologica, 2016, 235, 189-194.	1.0	8
47	Experimental Endoscopic Endovascular Cannulation: A Novel Approach to Thrombolysis in Retinal Vessel Occlusion. , 2012, 53, 42.		7
48	The significance of pigment epithelial detachment in central serous chorioretinopathy. European Journal of Ophthalmology, 2021, 31, 556-565.	0.7	7
49	Retinal Vein Occlusion Associated With Antithrombin Deficiency Secondary to a Novel G9840C Missense Mutation. JAMA Ophthalmology, 2006, 124, 1165.	2.6	6
50	Intravitreal Ranibizumab versus Isovolemic Hemodilution in the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion: Twelve-Month Results of a Prospective, Randomized, Multicenter Trial. Ophthalmologica, 2015, 233, 8-17.	1.0	6
51	Switching to intravitreal fluocinolone acetonide implant for refractory diabetic macular edema: 12- and 24-month results. European Journal of Ophthalmology, 2022, 32, 443-449.	0.7	4
52	Ranibizumab Pro Re nata versus Dexamethasone in the Management of Ischemic Retinal Vein Occlusion: Post-hoc Analysis from the COMRADE Trials. Current Eye Research, 2020, 45, 604-614.	0.7	3
53	Ophthalmic Outpatient and Inpatient Care Under Pandemic Conditions: Hygiene, Triage and New Challenges. Klinische Monatsblatter Fur Augenheilkunde, 2021, 238, 561-568.	0.3	3
54	Expression of Ubiquitin Carboxy-Terminal Hydrolase-L1 in Photocoagulated Human Retinal Pigment Epithelial Cells. Current Eye Research, 2007, 32, 367-372.	0.7	2

#	Article	IF	CITATIONS
55	Reply. American Journal of Ophthalmology, 2016, 169, 292-293.	1.7	2
56	tPA and gas in submacular hemorrhage: Author reply. Ophthalmology, 2002, 109, 825.	2.5	0
57	Minimally Invasive Surgical Treatment of Macular Hemorrhages. , 2018, , 33-47.		Ο
58	The urgency of surgical treatment for rhegmatogenous retinal detachment. Ophthalmologe, 2021, 118, 160-165.	0.4	0
59	Surgical Management of Choroidal Diseases. Klinische Monatsblatter Fur Augenheilkunde, 2021, 238, 980-987.	0.3	0
60	Authors' Response to correspondence: Pneumatic retinopexy–a critical reappraisal. Survey of Ophthalmology, 2021, 66, 900-901.	1.7	0
61	Authors' Response. Survey of Ophthalmology, 2021, 66, 1076-1078.	1.7	0